C. Frank Bennett
C. Frank Bennett is an American scientist known for his contributions to the field of genetics and neuroscience. He is a co-founder and the Senior Vice President of Research at Ionis Pharmaceuticals, a biotechnology company specializing in the development of antisense oligonucleotide therapies.
Early Life and Education
Bennett received his B.S. degree in Pharmacy from the University of New Mexico. He then went on to earn his Ph.D. in Pharmacology from the University of Pennsylvania.
Career
Bennett began his career in the pharmaceutical industry, focusing on the development of novel therapeutic approaches. In 1989, he co-founded Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals), where he has played a pivotal role in advancing the company's research and development efforts.
Contributions to Science
Bennett is widely recognized for his work in the development of antisense oligonucleotides, a class of drugs designed to target and regulate the expression of specific genes. His research has led to the development of several FDA-approved therapies, including Spinraza (nusinersen), the first treatment for spinal muscular atrophy (SMA).
Antisense Oligonucleotides
Antisense oligonucleotides are short, synthetic strands of nucleic acids that can bind to RNA molecules, modulating their function. This technology has been applied to treat a variety of genetic disorders, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and Duchenne muscular dystrophy.
Awards and Honors
Bennett has received numerous awards for his contributions to medical science, including the Oligonucleotide Therapeutics Society Lifetime Achievement Award and the American Chemical Society's Heroes of Chemistry Award.
Personal Life
Bennett resides in California and continues to be actively involved in research and development at Ionis Pharmaceuticals.
See Also
References
External Links
Template:Ionis Pharmaceuticals
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
